Watch Demo
Healthcare Innovation

Revolutionizing Cardiac Care: Cardio Diagnostics Partners with Ascension Borgess Hospital

The Key Ideas

• Revolutionizing Cardiac Care with AI

• Cardio Diagnostics and Ascension Borgess Hospital Partnership

• Potential Impact on Coronary Artery Disease Prevention

• Advancements in Cardiovascular Medicine Tests

A Pioneering Research Study in Cardiac Health

In an unprecedented move towards the future of cardiac care, Cardio Diagnostics Holdings, Inc., a trailblazer in artificial intelligence (AI)-driven precision cardiovascular medicine, has announced a significant partnership with Ascension Borgess Hospital. This collaboration is set to leverage groundbreaking AI-driven cardiovascular medicine tests in a novel coronary artery disease study, marking a significant milestone in the quest to advance heart disease prevention and treatment.

Under the leadership of Dr. Vishal Gupta, a renowned cardiologist and the head of the Heart Attack Prevention Clinic at Ascension Borgess, the study will utilize Cardio Diagnostics’ innovative Epi+Gen CHD and PrecisionCHD tests. These tests represent a leap forward in the integration of AI technology with genetic and epigenetic analysis to provide a more accurate assessment of coronary artery disease risk.

Advancing Heart Disease Prevention

The potential impact of this partnership on the prevention and treatment of coronary artery disease cannot be overstated. Coronary artery disease, the most common type of heart disease, remains a leading cause of death worldwide. Traditional methods of assessing risk and guiding treatment have relied heavily on lifestyle and physiological factors, but the advent of AI-driven tests introduces a new era where precision medicine becomes the cornerstone of cardiac care.

Cardio Diagnostics’ Epi+Gen CHD and PrecisionCHD tests stand at the forefront of this transformation. By combining genetic and epigenetic markers with AI algorithms, these tests offer a nuanced and comprehensive view of an individual’s risk for coronary artery disease. This approach not only enhances the accuracy of diagnoses but also opens the door for personalized treatment plans, tailored to the genetic makeup and environmental influences unique to each patient.

Shaping the Future of Cardiology

The collaboration between Cardio Diagnostics and Ascension Borgess Hospital is a testament to the shifting paradigms in healthcare, where technology and medicine converge to offer better outcomes for patients. The study spearheaded by Dr. Gupta is poised to provide invaluable insights into the effectiveness of AI-driven tests in clinical settings, potentially setting a new standard for cardiac care.

Moreover, this partnership highlights the growing importance of precision medicine in the field of cardiology. As healthcare continues to evolve, the integration of AI and genetic analysis in diagnostic and treatment processes is expected to become increasingly prevalent, offering hope for more effective prevention and management of cardiovascular diseases.


The initiative undertaken by Cardio Diagnostics and Ascension Borgess Hospital marks a significant step forward in the battle against coronary artery disease. By harnessing the power of AI-driven cardiovascular medicine tests, this pioneering research study promises to pave the way for advancements in heart disease prevention and treatment. As we look towards the future, the potential for these technologies to transform cardiac care is both immense and inspiring, offering a glimpse into a new era of personalized medicine tailored to the unique genetic and epigenetic landscape of each patient.

Marketing Banner